PS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial

Abstract Treatment with the interleukin-17A/F inhibitor bimekizumab (BKZ) has demonstrated maintenance of efficacy and health-related quality life (HRQoL) outcomes over 2 years. The objective this analysis was to assess long-term response in patients moderate-to-severe plaque psoriasis who achieved Psoriasis Area Severity Index (PASI) ≤ 2, a key treat-to-target outcome, after 16 weeks BKZ treatment 3 Patients completed 52- (BE VIVID) or 56-week SURE BE READY) phase III feeder study were eligible enrol BRIGHT open-label extension (OLE) (NCT03370133, NCT03412747, NCT03410992 NCT03598790). Upon OLE entry, received 320 mg Q4W Q8W based on week 52/56 PASI 90 (≥ 90% improvement PASI) response. switched from at 24 (based investigator discretion response), 48/next scheduled visit (all patients). Achievement body surface area (BSA) 1% 0 studies), Dermatology Life Quality (DLQI)0/1 READY only due schedule differences) is reported among responders through year 1 (feeder 52/56) (OLE 96). Analysed randomized BKZ, dosing entered OLE, including subset then continuous (Q4W/Q8W/Q8W). Missing data imputed using modified nonresponder imputation (mNRI): discontinued lack treatment-related adverse events considered nonresponders; multiple used for all other missing data. responder rate also (NRI). At baseline, 989 BKZ; 87.8% (n = 868) 16. Of these, 694 OLE. Among 694), 91.9% 82.3% BSA (52 weeks), 88.6% 74.1% 3, respectively. 445), 86.8% DLQI 0/1 (56 weeks) Q4W/Q8W/Q8W 189), 95.2% 87.6% 93.4% 79.7% years, patients, 94.1% 91.2% provided HRQoL benefits. responders, vast majority sustained high levels clinical responses years treatment, those Q4W/Q8W/Q8W. Funding: UCB Pharma. Medical writing: Costello Medical.